UNSPSC 51332836: Butaperazine dimaleate

This classification denotes a dopamine antagonist with the molecular formula C24H31N3OS.2C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 22VUW43J2H, chemically known as 1-(10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazin-2-yl)-1-butanone maleate (1:2), but more generally known as butaperazine dimaleate, which bears US NIH Compound Identifier 6433234. European Medicines Agency schedules butaperazine dimaleate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06007MIG.

Most nations, for tariff purposes, schedule butaperazine dimaleate under HS 29343090. SMILES: CCCC(=O)C1CC2C(CC1)SC3C(CCCC3)N2CCCN4CCN(CC4)C.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51332836 Butaperazine dimaleate is a Commodity code, yet the recent state and local contract opportunities tagged under it do not reflect procurement of this pharmaceutical compound specifically. Instead, the three opportunities posted between January and June 2026 track purchases of naloxone, generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription fulfillment services—none of which align with butaperazine dimaleate, an antipsychotic medication. The mismatch suggests either a tagging error in the source data or a departure between the code's nominal scope and the work being solicited under it. State and local health agencies, purchasing cooperatives, and HHS departments are active buyers in this space, but the recent activity does not support current procurement demand for butaperazine dimaleate itself.

Geographically, recent opportunities span Florida, Texas, and Minnesota through multi-state cooperative vehicles. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) for naloxone and drug deactivation systems; the Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) on direct-to-manufacturer prescriptions; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to serve participating state and local facilities across multiple jurisdictions including Oregon. None of these opportunities specifically target butaperazine dimaleate, and the code shows little relevant recent activity for the compound itself.